Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 8 | 2017 | 50 | 1.080 |
Why?
|
| Shock, Cardiogenic | 5 | 2025 | 17 | 0.900 |
Why?
|
| Heart-Assist Devices | 3 | 2024 | 53 | 0.670 |
Why?
|
| Cardiomyopathies | 3 | 2025 | 70 | 0.640 |
Why?
|
| Cardiology | 3 | 2024 | 110 | 0.510 |
Why?
|
| Heart Failure | 8 | 2025 | 780 | 0.500 |
Why?
|
| Hospital Mortality | 4 | 2025 | 207 | 0.330 |
Why?
|
| Registries | 4 | 2025 | 328 | 0.320 |
Why?
|
| Equipment Failure | 1 | 2010 | 29 | 0.320 |
Why?
|
| Bacteremia | 2 | 2022 | 69 | 0.250 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2024 | 31 | 0.220 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2024 | 9 | 0.210 |
Why?
|
| Myocardial Ischemia | 1 | 2025 | 114 | 0.210 |
Why?
|
| Respiratory Insufficiency | 1 | 2024 | 61 | 0.210 |
Why?
|
| Hemodynamics | 1 | 2023 | 168 | 0.190 |
Why?
|
| Critical Care | 4 | 2024 | 113 | 0.190 |
Why?
|
| Humans | 22 | 2025 | 34474 | 0.190 |
Why?
|
| Critical Illness | 1 | 2022 | 89 | 0.180 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 34 | 0.180 |
Why?
|
| Staphylococcal Infections | 1 | 2022 | 83 | 0.170 |
Why?
|
| Osteoporosis | 1 | 2002 | 74 | 0.170 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 63 | 0.160 |
Why?
|
| Tissue Donors | 2 | 2017 | 208 | 0.160 |
Why?
|
| Coronary Care Units | 3 | 2024 | 7 | 0.150 |
Why?
|
| Plasmapheresis | 1 | 1999 | 11 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1999 | 24 | 0.150 |
Why?
|
| Antibodies | 1 | 1999 | 59 | 0.150 |
Why?
|
| Preoperative Care | 1 | 1999 | 128 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2017 | 184 | 0.130 |
Why?
|
| Female | 11 | 2025 | 21490 | 0.130 |
Why?
|
| Heart Ventricles | 1 | 2017 | 155 | 0.120 |
Why?
|
| Palliative Care | 1 | 2016 | 52 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 87 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2016 | 130 | 0.110 |
Why?
|
| Cachexia | 1 | 2015 | 9 | 0.110 |
Why?
|
| Malnutrition | 1 | 2015 | 21 | 0.110 |
Why?
|
| Middle Aged | 8 | 2025 | 12703 | 0.110 |
Why?
|
| Male | 9 | 2025 | 20697 | 0.110 |
Why?
|
| Aged | 6 | 2025 | 10998 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2017 | 953 | 0.100 |
Why?
|
| Prognosis | 3 | 2024 | 1603 | 0.100 |
Why?
|
| Intensive Care Units | 2 | 2024 | 123 | 0.100 |
Why?
|
| Hospitalization | 1 | 2012 | 500 | 0.070 |
Why?
|
| Depression | 1 | 2012 | 458 | 0.070 |
Why?
|
| United States | 3 | 2024 | 4267 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2002 | 251 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 261 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2025 | 3812 | 0.070 |
Why?
|
| Cause of Death | 2 | 2024 | 245 | 0.060 |
Why?
|
| North America | 1 | 2024 | 34 | 0.050 |
Why?
|
| Time Factors | 3 | 2024 | 2352 | 0.050 |
Why?
|
| Graft Rejection | 3 | 2003 | 242 | 0.050 |
Why?
|
| Device Removal | 1 | 2024 | 44 | 0.050 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2004 | 2 | 0.050 |
Why?
|
| Chloroquine | 1 | 2004 | 3 | 0.050 |
Why?
|
| Lactates | 1 | 2023 | 3 | 0.050 |
Why?
|
| Antirheumatic Agents | 1 | 2004 | 31 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2004 | 40 | 0.050 |
Why?
|
| Vascular Resistance | 1 | 2023 | 33 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 120 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2003 | 40 | 0.050 |
Why?
|
| Hepatitis C | 1 | 2003 | 45 | 0.050 |
Why?
|
| Inflammation | 2 | 2015 | 557 | 0.050 |
Why?
|
| Methicillin | 1 | 2022 | 4 | 0.050 |
Why?
|
| Oxacillin | 1 | 2022 | 6 | 0.050 |
Why?
|
| Calcitonin | 1 | 2002 | 4 | 0.050 |
Why?
|
| Diphosphonates | 1 | 2002 | 9 | 0.050 |
Why?
|
| Adolescent | 1 | 2010 | 3799 | 0.050 |
Why?
|
| Survivors | 1 | 2003 | 177 | 0.050 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 58 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 325 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2002 | 96 | 0.040 |
Why?
|
| Quality of Life | 2 | 2017 | 1032 | 0.040 |
Why?
|
| Bone Density | 1 | 2002 | 208 | 0.040 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 1999 | 9 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 352 | 0.040 |
Why?
|
| Immunosuppression | 1 | 1999 | 120 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2024 | 1506 | 0.040 |
Why?
|
| Muromonab-CD3 | 1 | 1997 | 16 | 0.030 |
Why?
|
| Antilymphocyte Serum | 1 | 1997 | 40 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 1999 | 589 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1997 | 9 | 0.030 |
Why?
|
| Myocarditis | 1 | 1997 | 9 | 0.030 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1997 | 19 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 138 | 0.030 |
Why?
|
| Advance Care Planning | 1 | 2016 | 15 | 0.030 |
Why?
|
| Medicaid | 1 | 2016 | 103 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2017 | 287 | 0.030 |
Why?
|
| Family | 1 | 2016 | 123 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2016 | 272 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 1997 | 540 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2016 | 199 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2017 | 283 | 0.030 |
Why?
|
| Wasting Syndrome | 1 | 2015 | 14 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2016 | 149 | 0.030 |
Why?
|
| Appetite | 1 | 2015 | 24 | 0.030 |
Why?
|
| Medicare | 1 | 2016 | 217 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 193 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 378 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2015 | 80 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2017 | 440 | 0.030 |
Why?
|
| Survival Rate | 2 | 2012 | 925 | 0.030 |
Why?
|
| Risk Factors | 1 | 2002 | 4136 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 227 | 0.030 |
Why?
|
| Myocardium | 1 | 2015 | 199 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2015 | 169 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 2366 | 0.020 |
Why?
|
| Adult | 3 | 2003 | 10015 | 0.020 |
Why?
|
| Postoperative Complications | 3 | 2003 | 849 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2015 | 488 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2016 | 2461 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 4150 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 934 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 1910 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2003 | 7 | 0.010 |
Why?
|
| Illinois | 1 | 2003 | 11 | 0.010 |
Why?
|
| Hypertension, Pulmonary | 1 | 2003 | 23 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2003 | 7 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 2003 | 29 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 111 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 2003 | 47 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2003 | 44 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2003 | 49 | 0.010 |
Why?
|
| Heart Atria | 1 | 2003 | 84 | 0.010 |
Why?
|
| Cadaver | 1 | 2003 | 169 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 204 | 0.010 |
Why?
|
| Echocardiography | 1 | 2003 | 202 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2003 | 509 | 0.010 |
Why?
|
| Heart | 1 | 2003 | 191 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 922 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1997 | 318 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2003 | 3618 | 0.010 |
Why?
|
| Animals | 1 | 1997 | 8544 | 0.000 |
Why?
|